Oxathiazine derivatives as antibacterial and anticancer agents
New oxathiazin-like compounds and their derivatives are useful as antineoplastic and antimicrobial agents. Compositions and methods of using oxathiazin-like compounds and their derivatives are disclosed.
1. A pharmaceutical composition comprising at least one compound selected from:
and a pharmaceutically acceptable carrier.
2. The pharmaceutical composition of claim 1 , comprising about 0.01 to about 3% of said at least one compound.
3. The pharmaceutical composition of claim 1 , further comprising taurolidine and/or taurultam.
4. The pharmaceutical composition of claim 1 , comprising about 0.01 to about 1000 μg/ml of said at least one compound.
5. The pharmaceutical composition of claim 1 , wherein said composition is an injection and/or infusion formulation comprising a pharmaceutically acceptable injection or infusion carrier.
6. The pharmaceutical composition of claim 5 , wherein said pharmaceutically acceptable injection or infusion carrier comprises an isotonic solution.
7. The pharmaceutical composition of claim 5 , wherein said pharmaceutically acceptable injection or infusion carrier comprises one or more solubilizing agents.
8. The pharmaceutical composition of claim 5 , wherein said pharmaceutically acceptable injection or infusion carrier comprises a polyol.
9. A method of broadening the pharmacokinetic effects of taurolidine and/or taurultam in a human subject using at least two compounds having different half-lives, comprising administering to the human subject taurolidine and/or taurultam in combination with at least one compound selected from:
10. The method of claim 9 , wherein said method comprises administering a dosage of 0.1-1,000 mg/kg of said at least one compound in combination with a dosage of 0.01-500 mg/kg of taurolidine and/or taurultam.
11. The method of claim 9 , wherein said method comprises administering a total daily dose of about 0.1 g to about 100 g of said at least one compound in combination with a total daily dose of about 0.01 g to about 50 g of taurolidine and/or taurultam.
12. An oral dosage form comprising a pharmaceutically acceptable carrier suitable for an oral dosage form and at least one compound selected from:
13. The oral dosage form of claim 12 , wherein said oral dosage form is a capsule or a tablet.
14. The oral dosage form of claim 12 , wherein said compound is 2245.
15. The oral dosage form of claim 12 , wherein said compound is 2255.
16. The oral dosage form of claim 12 , wherein said compound is 2250.